Regional Biocontainment Lab Will Develop Vaccines for Biological Threats
The need for biocontainment laboratories to focus on products, vaccines, diagnostics, and therapeutics, became painfully clear following the post-9/11 anthrax attacks. Two national biocontainment labs currently are under construction; 13 regional labs are in various stages of design and construction; and when it is completed in October, Colorado State University's Rocky Mountain Regional Biocontainment Laboratory (RBL) will be the third regional laboratory to be completed in the country.

Detailed Processes Needed for Planning and Operating Safe Biocontainment Facilities
Rated Biosafety Level 3 (BSL-3), one of the newest labs at Lawrence Livermore National Laboratory (LLNL) in Livermore, Calif., enables research in the detection of potential threats and biological weapons including anthrax, botulism, and other diseases. The BSL-3 facility is a one-story, permanent, self-contained 1,600-sf building, with three individual laboratory rooms: an animal lab, a mechanical room, and shower/change rooms. The $2.45-million facility, funded by the Department of Homeland Security, was completed in 2005 and independently certified to be in compliance with the BMBL.

Innovative Nose-Only Exposure Techniques Create Safe Flexible Labs
The Health Protection Agency's (HPA) innovative "snout-only" aerosol exposure and biocontainment technique is driving significant research benefits, more efficient space use, and increased worker safety at the Centre for Emergency Preparedness and Response in Porton Down, U.K. HPA's highly accurate technique is based around the use of a modular aerosol generator and exposure system built inside a Class-III BSL cabinet. Nose-only delivery of aerosolized agents provides a controllable, accurate exposure system with a high degree of measurable safety that can be modified to accommodate different strategies for both rodent subjects and non-human primates.

Business Objectives and Process Flows Play a Key Role
Researching Select Agents such as anthrax or avian influenza frequently requires integrating animal housing into the high-containment microbiological research environment. However, incorporating these animal facilities into such an environment poses numerous challenges.

Minimize Energy Costs and Risks with Comprehensive Management Program
Rising energy prices have struck hard at nearly every industry in the United States, including commercial real estate, and price escalation and volatility are projected to continue indefinitely. Commercial building owners, representing more than 4.6 million buildings and nearly 65 billion square feet of space in the United States, spend nearly $93 billion on energy annually.1 With such a large spend on energy, it is clear that inaction, combined with current high prices and inevitable future price hikes, will have disastrous consequences for the corporate bottom line.

Protecting the Scientists, the Community, and the Environment
A growing number of emerging diseases and microbial threats to human and animal health have heightened the importance of properly designing, constructing, operating, and maintaining high-containment labs.

Biologics Produced in GMP Facility Lead to New Vaccines
In April of this year the U.S. Food and Drug Administration (FDA) announced the first approval in the United States of a vaccine for humans against the H5N1 influenza virus, commonly known as avian or bird flu. The announcement also marked a turning point for the new Good Manufacturing Practices (GMP) research facility at St. Jude Children's Research Hospital in Memphis, Tenn.

Part II Strategies for Process Improvement
Tradeline presents a two-part white paper on the strategic management of real estate in the financial services section. Part II of this paper will first describe two strategic approaches that involve the use of the IWMS solution. Then three metrics will be provided, which can be reported on using this solution and can be utilized to measure the success of these strategies for business.